Loading
Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer.
Marcia Brose was principal investigator of DECISION, the phase 3 trial that showed sorafenib doubles progression-free survival in radioiodine-refractory differentiated thyroid cancer and became the first targeted therapy approved for the disease in 40 years. She has led cabozantinib (COSMIC-311) and RET-inhibitor trials in thyroid cancer and chairs medical oncology at Jefferson.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer and the tag thyroid.
Shares Thyroid cancer and the tag thyroid.